Robinhood stock price: What to know about HOOD after its buyback push and January trading data

February 21, 2026
Robinhood stock price: What to know about HOOD after its buyback push and January trading data

New York, February 21, 2026, 14:26 (EST) — Market closed

  • HOOD finished Friday at $76.11, gaining 0.6%.
  • Robinhood reported platform assets of roughly $324 billion at the end of January, and kicked off share repurchases at a faster clip early in the quarter.
  • Goldman Sachs trimmed its price target to $111, though the firm stuck with a buy rating, citing consistent platform activity.

Robinhood Markets reported Thursday that customer holdings on its platform reached roughly $324 billion by the end of January. The company disclosed it had bought back about 2.1 million shares this quarter up through Feb. 17, spending $173 million at an average price near $84 per share. On Friday, Robinhood shares ended at $76.11, up 0.6%, after trading in a range from $75.12 to $78.01. 1

Investors don’t get many routine data drops between earnings, making the monthly snapshot a rare checkpoint. It’s a fast way to stack up performance against other retail brokers—think Charles Schwab, Interactive Brokers—or platforms deep in crypto like Coinbase.

That’s significant right now, as Robinhood works to show it can expand without relying on the waves of crypto excitement that fueled previous spikes. Investors eye the buyback speed closely; it’s an indicator of how much cash Robinhood is prepared to hand back while still putting money into fresh offerings.

Robinhood counted 27.2 million funded customers at January’s close, a gain of roughly 190,000 from December, according to the company. Net deposits hit $4.5 billion for the month. Equity notional trading volume jumped 21%, ending up at $227.3 billion. Crypto notional volume ticked up 8% to $22.9 billion. Traders moved 3.4 billion event contracts, up 17%. The company noted these monthly stats are unaudited, and it adjusted December platform assets to reflect updated crypto pricing. 2

Goldman Sachs’ James Yaro dropped his Robinhood target to $111, down from $130, but stuck with his Buy call on Friday, citing “robust” platform activity. Yaro flagged a 30% jump in app downloads month over month and noted “daily commissions”—used as a stand-in for daily transaction revenue—rose 13% to around $10 million. 3

Robinhood filed an amendment to its annual report on Friday, addressing some formatting glitches in tables and headings. The company emphasized the update didn’t impact any of its previously reported financial results. 4

Robinhood’s fourth-quarter revenue landed at $1.28 billion, coming up shy of the $1.34 billion analysts had penciled in, LSEG data showed, after a choppy digital asset market dented crypto trading. The stock fell following the results, which covered the quarter ending Dec. 31. 5

The monthly snapshot has its pitfalls: retail trading drops off quickly once markets calm, and swings in crypto and options volumes often come with little notice. If the tape slows, Robinhood’s transaction revenue would probably take a sharper hit than what more diversified brokers might see.

Markets are closed, so attention shifts to Monday’s open—traders want to see if momentum from the monthly snapshot holds, and whether moves in crypto or options spill into stocks. The next U.S. producer price index lands Feb. 27 at 8:30 a.m. ET. 6

Stock Market Today

  • Australia Hard Capsule Fill Excipients Market Analysis, Forecast to 2035
    April 3, 2026, 7:40 PM EDT. The Australia market for Hard Capsule Fill Excipients, key inactive ingredients used in pharmaceutical capsules, is analyzed in this strategic report. Covering historic data from 2012 to 2025 and forecasts to 2035, it provides insights into market size, supply chains, pricing mechanisms, and competitive dynamics. The report targets manufacturers, investors, and suppliers seeking clarity on market boundaries, demand drivers, regulatory landscape, and production challenges. It highlights critical issues like supply bottlenecks, cost drivers, and entry strategies, offering guidance on where growth opportunities and risks lie within this specialized segment of pharmaceutical ingredients.